AstraZeneca lifts UK investment pause, pledges £300 million for new office expansion

AstraZeneca announced on Wednesday that it is ending its pause on UK investment and will allocate £300 million to complete construction of a new office facility. The funding is intended to expand the company's presence in the United Kingdom and support its manufacturing and research activities.

The move follows recent discussions with the UK government that have restored a cooperative relationship between the two parties. AstraZeneca said the investment will create jobs and strengthen its long-term commitment to the UK market.

The company plans to finish the office build-out later this year, adding capacity for both corporate functions and scientific teams. The announcement signals confidence in the UK’s regulatory and business environment.

Analysts view the pledge as a positive signal for AstraZeneca's growth prospects and for the broader UK pharma sector.